BR112014013526A8 - conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados - Google Patents
conjugados de anticorpo-fármaco e compostos, composições e métodos relacionadosInfo
- Publication number
- BR112014013526A8 BR112014013526A8 BR112014013526A BR112014013526A BR112014013526A8 BR 112014013526 A8 BR112014013526 A8 BR 112014013526A8 BR 112014013526 A BR112014013526 A BR 112014013526A BR 112014013526 A BR112014013526 A BR 112014013526A BR 112014013526 A8 BR112014013526 A8 BR 112014013526A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- methods
- compositions
- related compounds
- drug conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
resumo patente de invenção: "conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados". a presente invenção refere-se a conjugados de anticorpo-citotoxina, anticorpo-fármaco e compostos relacionados, tais como conjugados de ligante-citotoxina e ligantes usados para fazê-los, análogos de tubulisina e síntese de intermediários; composições; e métodos, incluindo métodos de tratamento de cânceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566909P | 2011-12-05 | 2011-12-05 | |
PCT/US2012/067803 WO2013085925A1 (en) | 2011-12-05 | 2012-12-04 | Antibody-drug conjugates and related compounds, compositions, and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014013526A2 BR112014013526A2 (pt) | 2017-06-13 |
BR112014013526A8 true BR112014013526A8 (pt) | 2017-06-13 |
Family
ID=48574809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014013526A BR112014013526A8 (pt) | 2011-12-05 | 2012-12-04 | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
Country Status (17)
Country | Link |
---|---|
US (3) | US20130224228A1 (pt) |
EP (1) | EP2793585A4 (pt) |
JP (1) | JP2015500287A (pt) |
KR (1) | KR20140139480A (pt) |
CN (1) | CN104244718A (pt) |
AU (1) | AU2012348017A1 (pt) |
BR (1) | BR112014013526A8 (pt) |
CA (1) | CA2857398A1 (pt) |
HK (1) | HK1203309A1 (pt) |
IL (1) | IL232936A0 (pt) |
IN (1) | IN2014CN04961A (pt) |
MX (1) | MX2014006739A (pt) |
PH (1) | PH12014501229A1 (pt) |
RU (1) | RU2014124984A (pt) |
SG (1) | SG11201402686UA (pt) |
WO (1) | WO2013085925A1 (pt) |
ZA (1) | ZA201403946B (pt) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5149620B2 (ja) | 2004-07-23 | 2013-02-20 | エンドサイト,インコーポレイテッド | 2価リンカーおよびその結合体 |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
EP3925627A1 (en) * | 2012-05-15 | 2021-12-22 | Concortis Biosystems, Corp | Drug-conjugates and uses thereof |
US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
HUE048574T2 (hu) * | 2012-07-12 | 2020-08-28 | Hangzhou Dac Biotech Co Ltd | Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai |
IN2015DN04147A (pt) | 2012-10-16 | 2015-10-16 | Endocyte Inc | |
WO2014126836A1 (en) | 2013-02-14 | 2014-08-21 | Bristol-Myers Squibb Company | Tubulysin compounds, methods of making and use |
US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
US20140363454A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
FR3008408B1 (fr) * | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
SG11201601770YA (en) | 2013-09-12 | 2016-04-28 | Halozyme Inc | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
CA2934030A1 (en) * | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
ES2916722T3 (es) | 2013-12-27 | 2022-07-05 | Zymeworks Inc | Sistemas de enlace que contienen sulfonamida para conjugados de fármacos |
WO2015113760A1 (en) * | 2014-01-28 | 2015-08-06 | Tube Pharmaceuticals Gmbh | Cytotoxic tubulysin compounds for conjugation |
MX2016009332A (es) * | 2014-01-29 | 2016-12-20 | Shanghai hengrui pharmaceutical co ltd | Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo. |
GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
US10675352B2 (en) | 2014-02-14 | 2020-06-09 | Centrose, Llc | Extracellular targeted drug conjugates |
HUE045307T2 (hu) | 2014-03-11 | 2019-12-30 | Regeneron Pharma | EGFRVIII-ellenes antitestek és alkalmazásaik |
KR20160142392A (ko) * | 2014-04-11 | 2016-12-12 | 메디뮨 엘엘씨 | 튜부리신 유도체 |
CA2950155C (en) * | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
AU2015271749B2 (en) | 2014-06-03 | 2018-03-01 | Xbiotech Inc. | Compositions and methods for treating and preventing Staphylococcus aureus infections |
JP6473226B2 (ja) | 2014-09-11 | 2019-02-20 | シアトル ジェネティックス, インコーポレイテッド | 第3級アミン含有薬物物質の標的送達 |
PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
WO2016064749A2 (en) * | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
WO2016073845A1 (en) | 2014-11-07 | 2016-05-12 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
RU2017123942A (ru) | 2014-12-09 | 2019-01-11 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их |
CN113209306A (zh) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
US20160158377A1 (en) | 2014-12-09 | 2016-06-09 | Abbvie Inc. | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same |
MX2017009144A (es) | 2015-01-14 | 2017-11-22 | Bristol Myers Squibb Co | Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso. |
US10590165B2 (en) | 2015-01-28 | 2020-03-17 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
WO2016144608A1 (en) * | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
EP3273998B1 (en) | 2015-03-27 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
NZ737726A (en) | 2015-07-06 | 2023-03-31 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
PL3334462T3 (pl) * | 2015-08-14 | 2022-05-09 | RemeGen Biosciences, Inc. | Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania |
CA3006596A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | Anti-hulrrc15 antibody drug conjugates and methods for their use |
AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11229708B2 (en) * | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
IL259864B (en) | 2015-12-09 | 2022-07-01 | Univ Wien Med | Monomaleimide-functionalized platinum compounds for cancer therapy |
CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
US20190365913A1 (en) * | 2016-02-04 | 2019-12-05 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
WO2017201204A1 (en) | 2016-05-17 | 2017-11-23 | Abbvie Biotherapeutics Inc. | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
JP2019521106A (ja) | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗egfr抗体薬物コンジュゲート |
MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗cd98抗体及び抗体薬物コンジュゲート |
EP3835322A3 (en) | 2016-06-08 | 2021-10-06 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
EP3468596A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
US20200002421A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
EP3468615A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
CN109562152B (zh) * | 2016-08-09 | 2024-04-02 | 西雅图基因公司 | 含有具有改善的生理化学性质的自稳定性接头的药物缀合物 |
PL3515487T3 (pl) | 2016-09-23 | 2024-01-15 | Regeneron Pharmaceuticals, Inc. | Dwuswoiste przeciwciała anty-muc16-cd3 oraz koniugaty przeciwciało anty-muc16 - lek |
MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
IL266353B2 (en) | 2016-11-08 | 2024-03-01 | Regeneron Pharma | Steroids and their protein conjugates |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
KR20210122319A (ko) * | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
RU2020113749A (ru) * | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
MX2020006994A (es) | 2018-01-08 | 2020-11-06 | Regeneron Pharma | Esteroides y conjugados de anticuerpos de los mismos. |
CA3097711A1 (en) | 2018-04-30 | 2019-11-07 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
CA3098453A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
CN112220933A (zh) * | 2018-07-03 | 2021-01-15 | 烟台迈百瑞国际生物医药股份有限公司 | 抗体-t2毒素缀合物及其用途 |
EP3827266A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
US20210213116A1 (en) | 2018-07-26 | 2021-07-15 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
CA3106574A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
US20210162032A1 (en) | 2018-07-26 | 2021-06-03 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
CA3106573A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
CN116920115A (zh) * | 2018-12-17 | 2023-10-24 | 荣昌生物制药(烟台)股份有限公司 | 一种用于抗体药物偶联物的连接子及其应用 |
TW202039573A (zh) | 2018-12-21 | 2020-11-01 | 美商亞維代堤生物科學公司 | 抗轉鐵蛋白受體抗體及其用途 |
US11666658B2 (en) | 2018-12-21 | 2023-06-06 | Regeneran Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
KR20210130755A (ko) | 2019-02-21 | 2021-11-01 | 리제너론 파마슈티칼스 인코포레이티드 | 항-met 항체 및 met에 결합하는 이중특이적 항원 결합 분자를 사용하여 안구암을 치료하는 방법 |
EP3999118A1 (en) | 2019-07-19 | 2022-05-25 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
CN112569368A (zh) | 2019-08-07 | 2021-03-30 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2 and methods of using them |
CN115315446A (zh) | 2020-03-06 | 2022-11-08 | Go医疗股份有限公司 | 抗糖-cd44抗体及其用途 |
AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
JP2023527638A (ja) | 2020-03-27 | 2023-06-30 | アビディティー バイオサイエンシーズ,インク. | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
US11701427B2 (en) | 2020-04-16 | 2023-07-18 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
IL309173A (en) | 2020-07-13 | 2024-02-01 | Regeneron Pharma | Camptothecin analogs conjugated to a glutamine residue in protein, and their uses |
AU2021339892A1 (en) | 2020-09-14 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
CN116406379A (zh) | 2020-10-22 | 2023-07-07 | 瑞泽恩制药公司 | 抗fgfr2抗体和其使用方法 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
US11807685B2 (en) * | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
TW202325733A (zh) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | 抗醣化-lamp1抗體及其用途 |
US11912779B2 (en) | 2021-09-16 | 2024-02-27 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
US20230287138A1 (en) | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
US20230330254A1 (en) | 2022-03-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU725351B2 (en) * | 1995-01-26 | 2000-10-12 | Biogen Idec Ma Inc. | Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
EP2357006B1 (en) * | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
DE10254439A1 (de) * | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
BR122018071968B8 (pt) * | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
NZ580115A (en) * | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
WO2007034479A2 (en) * | 2005-09-20 | 2007-03-29 | Yissum Research Development Company | Nanoparticles for targeted delivery of active agents |
EP2224958A2 (en) * | 2007-11-30 | 2010-09-08 | Bristol-Myers Squibb Company | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
WO2010008726A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen Inc. | Novel synergistic effects |
JP6067222B2 (ja) * | 2008-07-15 | 2017-01-25 | ジェネンテック, インコーポレイテッド | アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途 |
EP2889624B1 (en) * | 2009-08-10 | 2018-10-03 | UCL Business PLC | Reversible covalent linkage of functional molecules |
EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
-
2012
- 2012-12-04 AU AU2012348017A patent/AU2012348017A1/en not_active Abandoned
- 2012-12-04 US US13/705,074 patent/US20130224228A1/en not_active Abandoned
- 2012-12-04 WO PCT/US2012/067803 patent/WO2013085925A1/en active Application Filing
- 2012-12-04 BR BR112014013526A patent/BR112014013526A8/pt not_active Application Discontinuation
- 2012-12-04 JP JP2014546004A patent/JP2015500287A/ja active Pending
- 2012-12-04 IN IN4961CHN2014 patent/IN2014CN04961A/en unknown
- 2012-12-04 KR KR1020147018663A patent/KR20140139480A/ko not_active Application Discontinuation
- 2012-12-04 SG SG11201402686UA patent/SG11201402686UA/en unknown
- 2012-12-04 MX MX2014006739A patent/MX2014006739A/es unknown
- 2012-12-04 CN CN201280067454.XA patent/CN104244718A/zh active Pending
- 2012-12-04 CA CA2857398A patent/CA2857398A1/en not_active Abandoned
- 2012-12-04 RU RU2014124984A patent/RU2014124984A/ru not_active Application Discontinuation
- 2012-12-04 EP EP12855849.1A patent/EP2793585A4/en not_active Withdrawn
-
2014
- 2014-05-29 ZA ZA2014/03946A patent/ZA201403946B/en unknown
- 2014-05-30 PH PH12014501229A patent/PH12014501229A1/en unknown
- 2014-06-02 IL IL232936A patent/IL232936A0/en unknown
-
2015
- 2015-04-29 HK HK15104134.2A patent/HK1203309A1/xx unknown
- 2015-08-24 US US14/834,078 patent/US20160303247A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,045 patent/US20200392108A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140139480A (ko) | 2014-12-05 |
IN2014CN04961A (pt) | 2015-09-18 |
BR112014013526A2 (pt) | 2017-06-13 |
SG11201402686UA (en) | 2014-06-27 |
US20160303247A1 (en) | 2016-10-20 |
HK1203309A1 (en) | 2015-10-30 |
PH12014501229A1 (en) | 2014-09-08 |
US20200392108A1 (en) | 2020-12-17 |
EP2793585A4 (en) | 2015-12-09 |
US20130224228A1 (en) | 2013-08-29 |
CN104244718A (zh) | 2014-12-24 |
EP2793585A1 (en) | 2014-10-29 |
CA2857398A1 (en) | 2013-06-13 |
AU2012348017A1 (en) | 2014-07-03 |
JP2015500287A (ja) | 2015-01-05 |
WO2013085925A1 (en) | 2013-06-13 |
MX2014006739A (es) | 2015-06-05 |
RU2014124984A (ru) | 2016-01-27 |
ZA201403946B (en) | 2015-09-30 |
IL232936A0 (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014013526A2 (pt) | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados | |
WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
MX367618B (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
NZ710729A (en) | Amatoxin derivatives | |
BR112014003477A2 (pt) | composições imunoterapêuticas de levedura-muc1 e usos das mesmas | |
CO6480975A2 (es) | Mimetico de smac | |
EA202190619A1 (ru) | Противовирусные соединения | |
UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
MX2013002417A (es) | Composiciones pesticidas. | |
MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
IN2015DN01119A (pt) | ||
MX2019001093A (es) | Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
MX2019010875A (es) | Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor. | |
BR112015000329A2 (pt) | formulações de diclofenac | |
MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). | |
BR112012030482A2 (pt) | tratamento de diabetes tipo 2 | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
BR112015003359A2 (pt) | pirrolopirazóis como bloqueadores de canal de cálcio de tipo-n | |
MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
MX2015014470A (es) | Analogos de combretastatina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |